Aclaris Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ACRS)

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.80. The biotechnology company had revenue of $0.98 million for the quarter, compared to analysts' expectations of $5.87 million. Aclaris Therapeutics had a negative return on equity of 83.22% and a negative net margin of 1,165.39%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 brokerages have issued 1-year price objectives for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 414.3% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

News coverage about ACRS stock has been trending somewhat negative this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,030,000 shares, an increase of 41.5% from the September 30th total of 4,260,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 3.1 days. Currently, 18.8% of the shares of the company are sold short. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include Urovant Sciences (UROV), Geron (GERN), Clovis Oncology (CLVS), Theratechnologies (THERF), Protagonist Therapeutics (PTGX), Avid Bioservices (CDMO), Corbus Pharmaceuticals (CRBP), AnaptysBio (ANAB), Satsuma Pharmaceuticals (STSA), Neptune Wellness Solutions (NEPT), GlycoMimetics (GLYC), Seres Therapeutics (MCRB), Applied Therapeutics (APLT), CytomX Therapeutics (CTMX) and BIOFRONTERA AG/ADR (BFRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Abeona Therapeutics (ABEO), BioDelivery Sciences International (BDSI) and Crispr Therapeutics (CRSP).

Aclaris Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.07%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.75.

Aclaris Therapeutics has a market capitalization of $72.43 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]